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ABSTRACT 
Background 
 There is increasing evidence that accumulation of ectopic fat in the heart such as 
epicardial adipose tissue (EAT) contribute to cardiovascular disease and myocardial 
dysfunction. These ectopic fat play important physiological roles in the regulation of glucose 
metabolism and as an energy source. However, in pathological conditions, they are pro-
inflammatory and secrete adipokines, which could accelerate atherosclerosis and cardiac 
remodeling. As these ectopic fats are well linked to conventional cardiovascular risk factors, 
previous studies have mainly investigated its association with coronary artery disease (CAD). 
The effects of EAT and non-obstructive coronary atherosclerosis on left ventricular (LV) 
myocardial function in those with preserved ejection fraction (EF) independent of other 
confounders such as diabetes and hypertension are unknown.  
 
Aims 
 The main aim of this research is to investigate the effect of EAT and non-obstructive 
coronary atherosclerosis on subclinical LV myocardial function using two-dimensional (2D) 
and three-dimensional (3D) speckle tracking echocardiography (STE) in patients with 
preserved LV EF. 
 
Methods 
 In the first study, 130 patients (53 ± 9 years, 53.1% male) with non-obstructive CAD 
(defined as <50% coronary stenosis by cardiac contrasted-enhanced CT) and preserved LV 
EF were enrolled prospectively. EAT volume was measured by cardiac CT and 
multidirectional global strains were evaluated by 3D STE.  
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 In the second study, 96 patients (51 ± 8.6 years, 56% male) without significant CAD, 
hypertension and diabetes were enrolled prospectively. The exclusion of patients with 
hypertension and diabetes eliminate other known confounders of LV strains. LV strains were 
evaluated by 2D and 3D STE.  
 Multivariable analyses were performed to investigate independent determinants of 2D 
and 3D multidirectional strains in each study. Additional analyses were performed to compare 
the predictive value of 2D versus 3D GLS for the presence of coronary atherosclerosis. 
 
Results 
In the first study, EAT volume measured by cardiac computed tomography (CT) was 
independently associated with 3D global longitudinal strain (GLS, r = 0.601; p < 0.001), 
global circumferential strain (GCS, r = 0.375; p < 0.001), global radial strain (GRS, 
r = −0.546; p < 0.001), and global area strain (GAS, r = 0.558; p < 0.001).  In multivariable 
analyses, EAT volume was the strongest predictor of 3D GLS (standardized β = 0.512; p < 
0.001), GCS (standardized β = 0.242; p = 0.006), GRS (standardized β = −0.422; p < 0.001), 
and GAS (standardized β = 0.428; p < 0.001). In contrast, other measures of obesity 
including BMI and waist/hip ratio were not independent determinants of 3D multidirectional 
global strain (all p > 0.05). 
In the second study, patients with non-obstructive CAD had lower 2D GLS (-18.5 ± 
2.2% vs. -20.1 ± 1.9%, p < 0.001) and 3D GLS (-14.9 ± 2.4% vs. -16.3 ± 3.1%, p = 0.011) 
compared to those without any coronary atherosclerosis. In multivariable analyses model 
using 2D GLS, both age (odd ratio = 2.16, p = 0.011) and 2D GLS (odd ratio = 1.55, p = 
0.001) were independent determinants of non-obstructive coronary atherosclerosis. When 2D 
GLS was replaced with 3D GLS in similar analyses, both age (odd ratio = 2.23, p = 0.007) 
and 3D GLS (odd ratio =1.21, p = 0.027) were also independent determinants of coronary 
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atherosclerosis. These associations were independent of obstructive CAD, diabetes and 
hypertension. 2D GLS was superior to 3D GLS in detecting coronary atherosclerosis using 
decision curve analysis despite having similar receiver operating characteristic curve derived 
area under the curves (2D GLS: 0.70 vs. 3D GLS: 0.65, p > 0.05). 
 
Conclusions 
EAT and non-obstructive coronary atherosclerosis are independent determinants of 
subclinical myocardial dysfunction, independent of significant CAD, diabetes and 
hypertension. Future studies are needed to explore the potential role of reducing EAT volume 
and management of early coronary atherosclerosis in prevention of progression of myocardial 
dysfunction especially in patients with metabolic and diabetic heart disease. 
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CHAPTER ONE 
Introduction 
Diabetes, hypertension, hypercholesterolaemia, obesity and obstructive coronary 
artery disease (CAD) are well-recognized risk factors for myocardial dysfunction (1-3). There 
is increasing evidence that ectopic accumulation of fat in the heart can increase 
cardiovascular risk and cause left ventricular (LV) dysfunction (4, 5). 
 This review will focus on the effect of cardiac ectopic fat such as epicardial adipose 
tissue (EAT) and non-obstructive coronary atherosclerosis on LV myocardial function. The 
role of two-dimensional (2D) and three-dimensional (3D) speckle-tracking echocardiography 
(STE) in the detection of subclinical myocardial dysfunction will also be discussed. 
 
1.1 Literature review 
1.1.1 Ectopic Fat 
 Ectopic fat is defined by excess adipose tissue in locations not classically associated 
with adipose tissue storage (6-8). In the heart, ectopic fat can accumulate in three different 
locations: intramyocardial, epicardial (bounded between the epicardium and the visceral 
pericardium) and pericardial (defined as external to the parietal pericardium) (6-8). 
 
1.1.2 Epicardial adipose tissue 
EAT is the true visceral fat depot of the heart that is derived from the 
splanchnopleuric mesoderm associated with the gut (2, 9).  It is of the same embryologic 
origin as mesenteric and omental fat cells, having evolved from brown adipose tissue during 
embryogenesis (2, 9). In human heart, EAT is commonly found in the atrioventricular and 
interventricular grooves (10-12). As no muscle fascia divides the epicardial fat and 
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myocardium, they share the same circulation (10, 12, 13). Its close anatomical proximity to 
the myocardium and coronary arteries leads to it having a dynamic effect on the working of 
the heart (12, 14-16). 
Under normal conditions, EAT is thought to serve a number of physiologic functions, 
including acting as an energy source to the myocardium (17, 18). Epicardial adipocytes are 
smaller in size than other fat depots (19). They possess different fatty acids composition and 
have higher rates of free fatty acids synthesis, uptake and release but lower rates of glucose 
utilization (19). This serves to capture and store intravascular free fatty acids to protect 
cardiac myocytes from exposure to excessive coronary arterial free fatty acids concentrations 
during increased energy intake and, at other times to release these fatty acids during periods 
of need (12, 20-23). However, it is only when the adipose tissues become dysfunctional, the 
term “lipotoxicity” is used to describe this impairment in tissue homeostasis attributable to 
alterations in lipid utilization, or lipid-induced changes in intracellular signaling (24). It has 
been proposed that cardiac lipotoxicity promote vascular endothelial and cardiac dysfunction 
through multiple synergistic signaling pathways such as microRNAs, epigenetic regulations 
and mitochondrial function (24). 
 In addition, EAT has been shown to produce several anti-inflammatory and anti-
atherogenic adipokines, such as adiponectin and adrenomedullin (10, 12, 16, 25, 26). 
However, it is a visceral fat deposit and as such has the capacity to secrete a number of 
cytokines and chemokines with pro-inflammatory and pro-atherogenic properties such as 
tumour necrosis factor-alpha, interleukin-6, resistin, leptin, plaminogen activator inhibitor-1 
and angiotensinogen (16, 23, 25, 27-29). What influences this equilibrium between harmful 
and possible protective effects is still unknown and is the key to understanding the 
pathophysiology of EAT and its link to cardiac lipotoxicity (11). 
 
 17 
1.1.2.1 Epicardial adipose tissue and coronary atherosclerosis 
1.1.2.1.1 Pathophysiology 
Most of the studies on the pathophysiology of EAT on cardiovascular disease 
stemmed from its association with atherosclerosis and vascular inflammation through its 
paracrine, vasocrine and mechanical effects (15, 16, 28, 30-33).  
EAT is ideally situated to have a paracrine effect on coronary arterioles as these is no 
tissue separating EAT and these blood vessels (16). In vivo studies where inflammatory 
cytokines were experimentally applied to the arterial adventitia have been shown to cause 
inflammatory changes by diffusion into the intimal layer (34, 35). Subsequently, both animal 
(21) and human studies confirmed the paracrine effect of EAT in promoting vascular 
inflammation (10, 36, 37). In particular, Mazurek and coworkers demonstrated inflammation 
was increased in EAT when compared to peripheral subcutaneous fat in patients with critical 
CAD undergoing coronary bypass graft surgery (36). Other studies also found an increase of 
CD45 mRNA expression in the EAT of subjects with CAD, representing elevated 
macrophage infiltration and a shift towards pro-inflammatory subpopulation of macrophages 
(38, 39) as well as an increase of mast cells and leucocyte common antigen positive cells in 
the adventitia of coronary lesions (40-42).  
Further evidence supporting the paracrine effect of EAT on development of CAD 
came from the studies of intramyocardial segments of coronary arteries (43-45). These 
intramyocardial segments are usually not surrounded by EAT and tend to be free of 
atherosclerotic lesions while the “kinked” segments surrounded by EAT often have 
atherosclerotic plaques (43-45).  
 Additionally, adipokines and free fatty acids might be released from EAT directly into 
the vasa vasorum and be transported downstream into the arterial wall according to a 
“vasocrine signalling” mechanism (15). EAT may also take part in regulation of 
 18 
vasoconstriction and vascular smooth muscle cell proliferation in coronary arteries. This 
hypothesis was derived from experimental studies that showed the release of relaxing 
factor(s) and protein growth factor(s) from perivascular fat (43-46). These factors exert anti-
contractile effect on smooth muscle cell and promote proliferation of smooth muscle cells 
(43-46). 
 EAT might also contribute to atherosclerosis through specific mechanical effects (47). 
For instance, under physiological conditions, EAT could attenuate coronary artery torsion 
(48). However, the presence of atherosclerotic plaque in coronary arteries leads to an 
asymmetric expansion of the vessel wall, known as positive vessel remodeling (48). Because 
of its intrinsic compressibility, EAT has therefore been suggested to play a permissive role in 
vessel expansion where coronary lesions surrounded by EAT can expand more easily (48). 
 
1.1.2.1.2 Clinical studies  
 There is a correlation between EAT and coronary atherosclerosis in patients with 
established CAD (49-52), suspected CAD (53-57), symptomatic patients with low-
intermediate risk of CAD (57-63), asymptomatic patients with low-intermediate risk of CAD 
(64, 65), and even in healthy patients (66-69). Interestingly, both Alexopoulos and coworkers 
and Oka and coworkers found that larger EAT volume was associated with non-calcified 
plaques compared to calcified plaques (57, 58). These non-calcified plaques were thought to 
be a feature of coronary vulnerability (57, 58). 
 A few studies have explored the relationship between EAT and coronary flow, which 
could indicate microvascular dysfunction and hence early atherosclerosis (13, 70-72). It was 
found that EAT correlated with reduced coronary flow reserve in patients with angina or 
electrocardiographic evidence of CAD but whose coronary arteries were angiographically 
normal (13, 70, 71). This could be secondary to vasoconstriction induced by EAT (43-46). 
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 In contrast, some studies did not demonstrate a correlation between EAT and CAD 
(73-75). Chaowalit and coworkers found no association between EAT thickness measured by 
2D echocardiography and CAD on angiography (73). The authors suggested that the 
biochemical, cellular and other functional characteristics of EAT might be more important in 
the pathophysiology of CAD than the total amount of EAT (73). Secondly, because EAT has 
a heterogeneous distribution around the heart, the 2D linear quantification of EAT may not be 
an accurate measurement for the total amount of EAT (11, 73). 
 
1.1.2.2 Epicardial adipose tissue and left ventricular function 
1.1.2.2.1 Pathophysiology 
 Increased visceral adiposity is one of the causes of adverse LV remodeling (76-79). 
Therefore, EAT may be a potential determinant of LV dysfunction. The effect of EAT on 
cardiac remodeling could be through its effect on coronary arteries as discussed in the 
previous section, or it could be a direct independent insult to the myocardium leading to 
enhanced myocardial hypertrophy, myocardial and perivascular fibrosis (6). 
 Autopsy and echocardiographic studies have shown that increasing EAT was 
associated with increasing LV mass that was independent of ischaemia (14, 80). The 
mechanism for such an association is unclear, but could be due to a combination of different 
factors (81). This includes the possible mechanical role of EAT in restricting the heart 
leading to decreased diastolic filling and atrial dilatation (82, 83). Additionally, the release of 
adipokines from EAT can induce cardiac remodeling and fibrosis (84, 85). 
Another mechanism linking EAT and myocardial dysfunction may be secondary to 
the intracellular accumulation of triglycerides (TG) and toxic products of free fatty acids and 
intermediate lipid metabolism (86). Free fatty acids are the major source of energy for the 
myocardium (87). Under normal conditions, the majority of free fatty acids undergo rapid 
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oxidation and little is stored (87). Under conditions of excess fatty acids, however, they are 
stored as TG and result in cardiac steatosis (87). When the amount of free acid accumulation 
exceeds the cellular oxidative capacity, free fatty acids are shunted into non-oxidative 
pathways, leading to accumulation of toxic intermediates such as diacylglycerol and ceramide 
that disrupt cellular signaling, eventually leading to cellular apoptosis, fibrosis and 
myocardial contractile dysfunction (87). Both animal and human studies have provided 
consistent evidence that these intracellular changes were associated with increased LV mass, 
impaired LV function and cardiac fibrosis (88-93). It has been suggested that free fatty acids 
could directly diffuse from EAT into myocardial cells, exacerbating myocardial steatosis and 
lipotoxicity, leading to adverse structural and functional cardiac adaptations (15, 94, 95). 
 EAT also can affect the heart through its systemic effects. It is closely associated with 
insulin resistance and glucose intolerance, and these conditions could also predispose 
independently to derangements in LV mass and function (81). 
 
1.1.2.2.2 Clinical studies 
 In small studies of healthy subjects with varying body mass indices, EAT thickness 
was found to be the strongest anthroprometric determinant of LV mass (7, 80). Similarly, 
larger population studies found that EAT volume was positively correlated with higher LV 
mass and larger left atrial dimension (82, 96). Subsequent studies in patients with 
conventional cardiovascular risk factors or CAD have also demonstrated an association 
between EAT, LV mass and diastolic dysfunction. For example, obese subjects with 
increased EAT had higher LV mass, impaired diastolic filling and enlarged atria, even after 
adjustment for body mass index (BMI), age and sex (84, 97, 98). Importantly, the amount and 
distribution of EAT vary widely between persons and are not strictly related to BMI or 
obesity (99). 
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 In untreated hypertensive patients, EAT was an independent predictor of LV mass 
(100, 101) and diastolic dysfunction (6, 102). In a small study of 43 patients, EAT and 
presence of hypertension were independently correlated with Tei index, a Doppler-based 
measurement of LV systolic and diastolic functions (23). Similarly, EAT was also related to 
LV diastolic dysfunction in patients with no previous history of CAD (81, 103), suspected or 
known CAD (75, 104, 105), as well as patients with metabolic syndrome (83, 106).  
 Interestingly, a few recent studies have demonstrated that EAT was reduced in 
patients with established mild to severe systolic dysfunction [LV ejection fraction (EF) < 
55%] (107-110). For example, Doesch and coworkers and Tabacki and coworkers enrolled 
patients with non-ischaemic dilated cardiomyopathy and found lower EAT burden in these 
patients (111, 112). The commonly observed lean and fat mass loss in patients with heart 
failure may explain the lower EAT volume in these patients (113). It has been postulated that 
as the myocardium becomes more dysfunctional and develops abnormal metabolic needs, the 
role of EAT as a source of energy or cytokine homeostasis would decrease, and as such, less 
would be found (36, 38, 109, 111). Additionally, natriuretic peptides seem to activate 
lipolysis in adipose tissue in patients with chronic heart failure (10). Consequently, increased 
level of such peptides contribute to decreased EAT volume in patients with chronic heart 
failure (112). These findings suggested a more complex interaction of regulatory pathways 
between EAT and myocardial contractile function.  
 A point to note is the main difference between studies showing reduced EAT in 
systolic dysfunction used EAT volume as the measurement parameter (108-112) whereas the 
studies with opposing results focused on linear EAT thickness measured using 4 chambers 
echocardiographic view (81, 112, 114). This was highlighted by Fluchter and coworkers who 
showed that “traditional” 2D echocardiographic EAT thickness measurements correlated 
poorly with 3D EAT volume measured by cardiac magnetic resonance imaging (CMR) in 
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patients with systolic dysfunction, suggesting EAT has an asymmetrical distribution in the 
heart (107).  
 
1.1.2.3 Measurement of epicardial adipose tissue 
 Numerous studies have measured EAT using various modalities including 
echocardiography (11, 59), CT (33), and CMR (58) while focusing on different measurement 
techniques (thickness or volume) (33). To further clarify the relationship between EAT and 
the development of cardiovascular disease, it is important to accurately and reproducibly 
quantify this adipose tissue. 
 
1.1.2.3.1 Echocardiography 
Standard parasternal long-axis and short-axis views from 2D images permit 
measurement of EAT thickness overlying the right ventricular free wall (9, 11). EAT is 
generally identified as the relatively echo-free space between the outer wall of the 
myocardium and the visceral layer of pericardium; its thickness is measured perpendicularly 
on the free wall of the right ventricle at end-systole in 3 cardiac cycles (11). EAT thickness in 
the short axis view (instead of 4 chambers view) has been shown to correlate well with EAT 
mass (107).  
Quantification of EAT by echocardiography has several advantages (11). Firstly, it is 
a direct measure of visceral fat deposition. Secondly, it is non-invasive, readily available, and 
less expensive than CT or CMR. Thirdly, it can be quantified in conjunction with other 
echocardiographic parameters such as LV mass and EF, which are traditionally associated 
with cardiovascular risks (11). 
However, it is limited due to its dependence on the acoustic window and provides 
only 2D linear measurement (11, 64). Therefore, this measurement may not reflect the 
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variability of EAT thickness or total EAT volume (11). In addition, there is poor 
reproducibility (115). Other potential limitations of echocardiography also include difficulty 
in differentiating between epicardial and pericardial fat (11). 
 
1.1.2.3.2 Cardiac computed tomography  
EAT can be quantified by CT on the basis of thresholds for CT attenuation (99). The 
software produces an accurate volume of EAT by adding EAT areas of 25 to 30 sections and 
multiplying by slice thickness (33). Different anatomic boundaries for measurement of total 
EAT volumes have been reported and include the pulmonary artery bifurcation, the mid left 
atrium, and the aortic root as upper boundaries and the diaphragm and the left ventricular 
apex as lower boundaries (99). 
The advantages of CT are its accuracy due to high spatial resolution and 
reproducibility (15, 33, 64, 116, 117). Furthermore, the pericardium is readily identified, 
resulting in easy differentiation between epi- and pericardial adipose tissue (66, 117). 
However, its drawbacks are it is time consuming and exposes patients to radiation (33, 59, 
107). 
 
1.1.2.3.3 Cardiac magnetic resonance imaging 
The benefit of CMR is similar to CT when compared to echocardiographic 
measurement of EAT. Its superiority over CT is lack of harmful radiation exposure. Similar 
to CT measurement of EAT volume, regions of interest are manually drawn along the borders 
of fat surrounding the heart from the apex to the pulmonary trunk (118). EAT areas are 
multiplied by slice thickness and can be converted in grams by using fat density of 0.9196 
g/ml as previously published (119). Its disadvantages include long scan time and known 
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contraindications to magnetic resonance imaging such as non-magnetic resonance compatible 
implantable devices, severe claustrophobia and severe renal impairment (120). 
 
1.1.3 Assessment of left ventricular myocardial function 
LV EF is the most commonly used clinical measurement of LV systolic function 
(121). However, it has several limitations. First, it does not always reflect intrinsic 
myocardial function (121). Secondly, it has limited prognostic value in the low-normal or 
higher range (122). Thirdly, any reduction in EF represents advanced LV functional 
impairment (123). Therefore, assessment of myocardial strain and strain rate using STE has 
gained recent popularity as it allows early detection of subclinical LV myocardial dysfunction 
(123). This opens the door to more aggressive treatment of early disease, rather than 
treatment of risk factors alone (124). 
 
1.1.4 Speckle tracking echocardiography 
Myocardial deformation analysis has evolved from one-dimensional assessment using 
tissue Doppler imaging to 2D and 3D STE (125, 126).  
STE is based on an analysis of the spatial dislocation (referred to as tracking) of 
speckles (defined as spots generated by the interaction between the ultrasound beam and 
myocardial fibres) on routine echocardiographic images (127). This allows semi-automated 
quantification of myocardial deformation (i.e. strain and strain rate) in 3 spatial directions: 
longitudinal, circumferential and radial (123). In addition, STE also permits quantization of 
LV rotation and torsion (127).  STE has been proven to provide incremental value beyond LV 
EF in predicting cardiac events and prognosis in various cardiac disorders (124).  
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1.1.4.1 Two-dimensional speckle-tracking echocardiography 
 2D STE measurements have been shown to correlate well with data obtained with 
tagged magnetic resonance imaging (the current “gold standard” for deformation analysis), 
both in normal myocardial segments and infarcted areas (128).  
 
1.1.4.1.1 Limitations of two-dimensional speckle-tracking echocardiography  
The whole heart moves through the 2D plane of interest due to torsion. Therefore, the 
2D plane of interest disappears through the cardiac cycle, and is known as the “through-
plane” or “out-of plane phenomenon” (121). This cause artefact in 2D STE. 
In addition, technical factors such as image quality, choice of segmentation model, 
selection of image clip, fiducial landmarks and segmental contouring as well as region of 
interest can affect strain values (129).  The variability of strain can also stem from 
intervendor and interobserver/intraobserver repeating testing (130). Previous studies on 2D 
STE have shown significant between and within manufacturer variability in measurements; 
this has impeded the transition of strain imaging from a research to a clinical tool in the past. 
However, Farsalinos and co-authors recently demonstrated the small differences between 
vendors and inter- and intraobserver were comparable to that of measurement of LV EF 
(131). 
 
1.1.4.2 Three-dimensional speckle-tracking echocardiography 
3D STE has recently been introduced as a method to measure cardiac deformation and 
volumes, and preliminary results have shown 3D STE indices detect subclinical LV 
dysfunction in those with risk factors for heart failure (132). 
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 Compared to 2D STE, which cannot track myocardial motion occurring out of plane, 
3D STE can track motion of speckles within the scan volume, irrespective of its direction 
(133). Thus, in addition to strain measurements of longitudinal, radial, and circumferential 
deformation, as well as combinations of these, rotation and twist parameters can also be 
quantified. Area strain, which combines the analysis of both longitudinal and circumferential 
deformations of the LV, offers quantification of endocardial area change (134, 135). In 
addition, 3D STE can assess a higher proportion of myocardial segments and is able to 
acquire and analyse 3D dataset (121, 134, 136-140).  
 
1.1.4.2.1 Limitations of three-dimensional speckle tracking echocardiography 
Despite the numerous theoretical advantages of 3D STE, it can be limited by image 
quality and therefore reduced accuracy (141). The relatively low frame rate and spatial 
resolution of 3D wall motion tracking can also affect the delineation of endocardial and 
epicardial surfaces and, in turn, the accuracy of tracking (141, 142). Furthermore, stitch 
artefacts can be inevitable in uncooperative patients and in those with cardiac arrhythmias 
(141). Similar to earlier work on 2D STE, inter-technique agreement is suboptimal, both for 
images acquired from different machines and images acquired from the same machine using 
different software (143).  
Functional non-uniformity is found in normal LV in 3D strain measurements where 
the average value of strain differed significantly between individual segments as well as 
between different walls and levels of the LV (130). In general, normal values of 
circumferential and area strains were most consistent with only marginally differences found 
between different segments, walls, and levels in healthy volunteers while global strain has the 
best reproducibility as compared to segmental strain measurements (130). Therefore, 
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choosing a robust 3D strain parameter for clinical practice can be another challenge and may 
affect the validity of segmental strain assessment. 
 
1.1.4.3 Two-dimensional versus three-dimensional speckle-tracking echocardiography 
The comparison between 2D and 3D strains has been challenging for various reasons, 
(1) the inherent technical issues underlying these 2 imaging modalities as previously 
mentioned, (2) the wide range of normal strain values with some overlap between 
physiological and pathological states, (3) the use of global versus segmental strain in terms of 
feasibility and reproducibility, and (4) the current conflicting literatures which is mainly 
limited by small study cohorts and significant heterogeneity between studies. 
It is still unclear which modalities is better despite 3D imaging’s theoretical 
advantages. 
 
1.1.4.3.1 Strain parameters in two-dimensional and three-dimensional speckle-tracking 
echocardiography 
Global longitudinal strain (GLS) has been shown to be the most robust of the 
deformation markers, reflecting the favourable effect of averaging when individual 
measurements are subjected to noise (124). The other advantages of using GLS include (i) 
images obtained in the axial plane have superior resolution; (ii) there is a greater amount of 
myocardial tissue in the apical long axis than in the short-axis view of the non-hypertrophied 
heart (129). 
 Though a few studies have found that 2D GLS is comparable to 3D GLS in different 
cohort of patients with varying LV function from preserved LV function (136) to moderate-
severe LV dysfunction (126, 144, 145), it is more widely recognized that these two are not 
interchangeable (137, 146-149). LS and radial strain (RS) by 3D STE are significantly 
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smaller than by 2D STE, whereas circumferential strain (CS) is significantly larger using 3D 
STE (139).  
 
1.1.4.3.2 Determinants of strain 
Strain parameters are influenced by both patient (age, gender, race, ethnicity, 
anthropometric), haemodynamic (heart rate, blood pressure), and cardiac factors (LV size, 
wall thickness) (150). In addition, hypertension (151, 152), diabetes mellitus (153, 154), 
dialysis (155) and CAD (156)  affect strain (129). These factors may act as potential 
confounders when interpreting the literature on STE especially when some of these co-
morbidities commonly co-exist. 
 
1.1.4.4 Speckle-tracking echocardiography in coronary artery disease 
 Obstructive CAD has been shown to cause subclinical LV dysfunction despite 
preservation of conventional indices of systolic LV function and no overt infarction (156). 
This could be secondary to small vessel microembolisation, endothelial dysfunction, or 
chronic ischaemia (157). 
Consistently, 2D GLS has been shown to predict the presence of significant CAD (89, 
158-169). In addition, 2D GLS declines incrementally with increasing severity of CAD 
defined by increasing number of stenotic coronary vessels (162, 163). It may also increase the 
diagnostic accuracy and sensitivity of stress echocardiography and complements 
conventional wall motion assessment (158, 163). Interestingly, 2D GLS measurement during 
stress echocardiography resulted in better diagnostic accuracy for CAD than their resting 
values (167, 169). 
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Conversely, Smedsrud and co-authors investigated the predictive value of 2D GLS in 
detecting significant CAD is only modest in patients with stable chest pain undergoing 
elective coronary angiography (164). This is further supported by a large prospective 
multicenter study demonstrating considerable overlap in the distribution of 2D GLS between 
those with and without acute coronary syndrome (170). A recent metaanalysis revealed 
similar conclusion (171). This could partly be explained by the fact that CAD is a primarily a 
regional problem and GLS is a global assessment of LV (171). Previously regional LS has 
shown greater potential in detecting CAD (172) but its use remains a challenge due to the 
heterogeneity in obtaining regional strain data (171). 
 The use of 3D STE in diagnosing and managing patients with CAD is also 
challenged by inconsistency in the literature in terms of defining the severity of CAD and 
degree of LV impairment in the study population, as well as the choice of strain 
measurements.  
In patients with LV regional wall abnormalities, AS has been shown to correlate well 
with LV EF and wall motion score index in a heterogeneous group of patients with different 
cardiac conditions including CAD (173). Additionally, regional strain by 3D STE is superior 
to 2D STE for detecting transmural scar in those with ischaemic cardiomyopathy (144). 
Regional LS by 3D STE, not 2D STE decreases early when the transmural scar is <25% 
whereas regional RS by 3D STE is decreased only when transmural scar is full thickness. 
This is consistent with findings from Altman and co-workers where 3D global and regional 
strain predicted recovery of LV EF after ST-elevation myocardial infarction (134).  
In patients with preserved LV EF, Li and coworkers demonstrated 3D multidirectional 
strain is predictive of moderate and severe CAD (174). Conversely, Sun and coworkers did 
not find 3D multidirectional peak strains diagnostic of early CAD in the cohort of patients 
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with chest pain (175). Instead, they found that a composite measurement of peak LS and time 
to peak LS was predictive of significant CAD (175).  
Only one study has compared 2D and 3D strain in patients with CAD. There is a good 
correlation between 2D GLS and 3D multidirectional strain in patients undergoing 
percutaneous coronary intervention (176). To date, the role of 2D versus 3D strain in patients 
with non-obstructive CAD and their predictive values remain uncertain. 
 
1.1.5 Discussion 
There are gaps in current literature with regards to the role of EAT and non-
obstructive CAD in myocardial dysfunction. First, although there is an association between 
EAT and the subsequent development of cardiac dysfunction, the published studies included 
small number of patients with multiple cardiovascular risks factors including obstructive 
CAD, hypertension and diabetes which could have confounded the results.  Secondly, the 
different methods for EAT quantification with variable reproducibility has been flagged as a 
major issue. Lastly, although 2D STE is a widely used tool in the quantification of 
myocardial function, 3D STE is still at its infancy. Further work needs to be done to evaluate 
the role of 3D STE in identifying subclinical myocardial dysfunction and how it is 
comparable to its 2D STE in patients with non-obstructive CAD and their values in predicting 
CAD. 
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CHAPTER TWO 
Aims and hypotheses of research  
2.1 Aims 
1. Investigate the association between EAT and myocardial function using 3D STE in 
patients with non-obstructive CAD. 
2. The comparison of 2D versus 3D STE in patients without obstructive CAD, diabetes 
and hypertension. 
 
2.2 Hypotheses 
1. EAT is an independent determinant of myocardial function independent of non-
obstructive CAD and other cardiovascular risk factors. 
2. 3D STE is superior to 2D STE in predicting presence of coronary atherosclerosis in 
patients without obstructive CAD, diabetes and hypertension.  
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Publication has been included in chapter three as previously stated (refer to page 6). I 
have a major role in the conception and design of this study, collection of research data, the 
analysis and interpretation of the research data on which the publication is based and co-
wrote the publication as a joint first author in conjunction with my principal advisor. 
 
CHAPTER THREE 
The association of epicardial adipose tissue and subclinical myocardial dysfunction 
using three-dimensional speckle tracking echocardiography in patients with non-
obstructive coronary artery disease 
 
3.1 Aims 
We aimed to identify independent determinants of EAT on cardiac CT in patients 
with non-obstructive CAD, and evaluate the association between EAT and myocardial 
function using 3D STE multidirectional global strain analysis. 
 
3.2 Methods 
3.2.1 Patient population and study protocol 
130 patients who presented with low risk chest pain to a tertiary hospital were 
prospectively recruited to undergo contrast-enhanced cardiac CT and 3D echocardiography. 
Contrast-enhanced cardiac CT was used to assess for the presence and severity of coronary 
atherosclerosis as well as to quantify EAT volume (see below). 3D echocardiographic 
examination included quantifications of 3D LV mass index, end-diastolic volume index 
(EDVI), end-systolic volume index (ESVI), LV EF and 3D multidirectional global strain 
[including GLS, global circumferential strain (GSC), global radial strain (GRS) and global 
area strain (GAS)].  
 33 
Exclusion criteria in the present study included LV EF <50% or previous 
cardiomyopathies or heart failure, moderate or severe valvular heart disease, congenital heart 
disease, previous history of CAD, obstructive CAD on contrast-enhanced cardiac CT defined 
as >50% coronary stenosis, atrial fibrillation and contraindications for cardiac CT 
examination. Contraindications for cardiac CT examination included supraventricular or 
ventricular arrhythmias, renal insufficiency defined as a glomerular filtration rate < 30 
mL/min/1.73m2, known iodine contrast allergy, severe claustrophobia, and pregnancy. In 6 
patients with intermediate CAD stenosis (i.e. 50% stenosis), ischaemia was excluded by 
stress echocardiography (n = 5) or stress technetium-99m sestamibi myocardial perfusion 
scan (n = 1).  
The mean and median dose-length product for the cardiac CT examination (including 
calcium scoring and contrast-enhanced CT coronary angiography) were 368.2 ± 302.6 
mGy.cm and 313.0 mGy.cm (25th and 75th percentile, 164.0 and 490.0 mGy.cm) respectively. 
Using a conversion factor of 0.014 for chest CT in adults (177), the mean and median 
estimated effective radiation dose were 5.2 ± 4.2 mSv and 4.4 mSv (25th and 75th percentile, 
2.3 and 6.9 mSv) respectively. 
The median time difference between cardiac CT and echocardiography was 1.0 month 
(25th and 75th percentile, 0.4 and 1.7 months). 
The study was approved by the institutional ethics committee. 
 
3.2.2 Cardiac CT data acquisition  
All patients underwent cardiac CT using a dual-source CT system (Somatom 
Definition Flash, Siemens Healthcare, Forchheim, Germany). Cardiac CT was acquired using 
prospective ECG gating triggered at 60% of the R-R interval, with a collimation of 2 x 128 x 
0.6mm and a gantry rotation time of 280ms. The tube current was 80mA.s and tube voltage 
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was 100 kV or 120 kV as determined by patient’s BMI. From the raw data, cross-sectional 
images were reconstructed with 0.75mm slice thickness and a soft reconstruction kernel 
(Siemens B26f). 
Patient’s heart rate and blood pressure were monitored prior to each scan and beta-
blockers (25 to 100mg Metoprolol orally) were administered in the absence of 
contraindications. All scans were performed during mid-inspiratory breath-hold and 75 mL of 
Ioversol (Optiray 350, Mallinckrodt Medical, St. Louis, MO) was injected into the antecubital 
vein. All cardiac CT images were subsequently exported to dedicated workstations 
(SyngoVia, Siemens Healthcare, Forchheim, Germany; MASS V2010-EXP, Leiden 
University Medical Center, Leiden, The Netherlands) for off-line post-processing.  
 
3.2.3 Epicardial adipose tissue quantification 
For EAT volume quantification, the pericardium was manually traced on every single 
cross-sectional image, starting from the level of the pulmonary artery bifurcation to the level 
of the diaphragm (Figure 1). Within these contour limits, a CT attenuation threshold of -50 to 
-200 Hounsfield Unit was used to isolate EAT as previously published (99, 178). Mediastinal 
fat and pericardial fat (outside the visceral pericardium and on the external surface of the 
parietal pericardium) were excluded. 
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Figure 1. Quantification of epicardial adipose tissue on cardiac CT.  
 
Epicardial adipose tissue is defined as fat between the heart and the fibrous pericardium, 
whereas paracardial adipose tissue is external to the pericardium (left panel). Contours were 
drawn along the pericardium and epicardial adipose tissue is automatically identified by the 
software (red colour) (right panel). 
 
3.2.4 Echocardiography 
Transthoracic echocardiography was performed with the subjects at rest using a 
commercially available ultrasound system (Vivid E9, 4V probe, GE-Vingmed, Horten, 
Norway). A complete 2D, 3D, colour, pulsed and continuous-wave Doppler echocardiogram 
was performed (179, 180). Image contrast, depth and sector size were optimized during 
image acquisition, with care taken to avoid foreshortened views, to include the entire 
myocardial wall, and an optimal frame rate of > 30 frames per second. Images were obtained 
during breath-hold to achieve a multi-beat 3D volume of a minimum of 4 heartbeats without 
artifacts (Figure 2). All images were digitally stored on hard disks for offline analysis. 3D LV 
mass index, LV EDVI, and LV ESVI were calculated using the 3D dataset and corrected for 
body surface area (181). LV EF was calculated and expressed as a percentage.  
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3.2.4.1 Three-dimensional speckle tracking echocardiography 
 3D multidirectional global strains were calculated from the 3D dataset using 
commercially available software (4D Auto LVQ, EchoPAC version 113, GE-Vingmed, 
Horten, Norway). Briefly, 3D volume datasets were initially displayed as conventional apical 
and short axis views (Figure 2). Automatic LV border contours were created after placing 2 
points, one at the center of the LV base and the other at the apex, in the end-diastolic and 
end-systolic apical views. The LV epicardial and endocardial border contours were adjusted 
if required. The motion of the 3D myocardium was subsequently tracked automatically 
throughout the entire cardiac cycle and myocardial deformation was calculated for each 
segmental volume. A multidirectional 17 segments Bull’s eye map with 3D GLS, GCS, GRS 
and GAS results were finally generated and displayed. 
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Figure 2. A representative graphical display of EAT volumes traced on CT and speckle 
tracking on 3D echocardiography for 2 patients. 
 
Examples of 3D STE in 2 female patients with 54.3cm3 and 129.0cm3 of epicardial adipose 
tissue respectively. Both patients had comparable LV mass index, volumes and EF, but 3D 
GLS was significantly more impaired in the patient with larger epicardial adipose tissue 
volume.  
3D: 3-dimensional; EAT: epicardial adipose tissue; EDVI: end-diastolic volume index; ESVI: 
end-systolic volume index; EF: ejection fraction; GLS: global longitudinal strain; LV: left 
ventricular; LVMI: left ventricular mass index. 
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3.2.5 Statistical Analysis 
All continuous variables were tested for Gaussian distribution. Continuous variables 
were presented as mean ± 1 standard deviation unless otherwise stated. Categorical variables 
were presented as frequencies and percentages, and were compared using Chi-square test 
when all expected cell counts were ≥ 5, or Fisher’s exact test if expected cell count was < 5. 
Unpaired Student’s t-test was used to compare 2 groups of continuous variables of Gaussian 
distribution. Pearson correlation was used to determine the association between 2 continuous 
variables. Multiple linear regression analyses were performed to identify independent 
determinants of both EAT volume and 3D multidirectional GLS, GCS, GRS and GAS with 
significant univariable determinants entered simultaneously as covariates. To avoid 
multicollinearity, a tolerance of > 0.4 (equating to a Variance Inflation Factor of > 2.5) was 
set. As the presence of diabetes, hypertension and non-obstructive coronary atherosclerosis 
may potentially confound the multidirectional global strain analyses, these variables were 
forced into all the multivariable models. In addition, to further confirm the study results, all 
multivariable analyses were repeated in patients without diabetes, hypertension and coronary 
atherosclerosis. Similarly, all analyses were repeated in patients with BMI ≤ 25.0 kg/m2 to 
exclude suboptimal image quality due to obesity as a confounding factor in artificially 
reducing the 3D multidirectional global strain measurements. In 10 randomly selected 
subjects, intra- and inter-observer measurement variabilities for EAT volume and 3D 
multidirectional global strain were presented as mean absolute differences. A 2-tailed p value 
of < 0.05 was considered significant. All statistical analyses were performed using IBM SPSS 
Statistics, version 21.0 (Armonk, NY). 
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3.3 Results 
 Table 1 outlines the baseline clinical, cardiac CT and echocardiographic 
characteristics for all the patients. The mean age was 53 ± 9 years, 53.1% male. Men were 
younger (50 ± 9 vs. 56 ± 8 years, p < 0.001) had significantly higher waist/hip ratio (0.97 ± 
0.06 vs. 0.89 ± 0.06, p < 0.001), and less likely to have a history of hypertension (p = 0.01). 
The mean EAT volume on cardiac CT was 97.5 ± 43.7 cm3 (range 20.0 – 235.2 cm3). 
Although there was a trend towards larger EAT volume in men (103.7 ± 39.5 vs. 90.4 ± 47.4 
cm3, p = 0.08), and there were no gender differences in the presence or absence of coronary 
atherosclerosis (p = 0.19) or Agatston calcium score (56.2 ± 130.2 vs. 34.6 ± 109.7, p = 0.31).  
Patients with evidence of coronary atherosclerosis had significantly larger EAT 
volume (107.4 ± 44.9 vs. 84.4 ± 38.8 cm3, p = 0.003). However, there was no correlation 
between EAT volume and Agatston calcium score (r = 0.089, p = 0.32). 
Finally, on 3D echocardiography, men had significantly larger LV volumes and lower 
3D multidirectional global strain (Table 1). Although there was a gender difference in LV EF, 
all patients had normal LV EF. 
 
Table 1. Baseline clinical, cardiac computed tomography and echocardiographic 
characteristics 
Variable Total 
population 
(n = 130) 
Male 
 
(n = 69) 
Female 
 
(n = 61) 
p value 
Clinical 
Age (years) 53 ± 9 50 ± 9 56 ± 8 < 0.001 
Body mass index (kg/m2) 28.2 ± 5.3 27.8 ± 5.4 28.6 ± 5.3 0.38 
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Waist/hip ratio 0.93 ± 0.07 0.97 ± 0.06 0.89 ± 0.06 < 0.001 
Hypertension (%) 30.0 20.3 41.0 0.010 
Diabetes (%) 10.0 11.6 8.2 0.52 
Hypercholesterolemia (%) 36.9 34.8 39.3 0.59 
Heart rate (beats/min) 70 ± 11 69 ±10 71 ± 12 0.27 
Systolic BP (mmHg) 133 ± 16 132 ± 15 134 ± 18 0.43 
Diastolic BP (mmHg) 81 ± 10 81 ± 9 81 ± 12 0.77 
Cardiac CT 
Presence of coronary 
atherosclerosis (%) 
56.9 62.3 50.8 0.19 
Agatston calcium score 46.1 ± 121.0 56.2 ± 130.2 34.6 ± 109.7 0.31 
Epicardial adipose tissue volume 
(cm3) 
97.5 ± 43.7 103.7 ± 39.5 90.9 ± 47.4 0.08 
3D Echocardiography 
LV mass index (g/m2) 72.4 ± 9.3 72.9 ± 8.8 71.8 ± 9.7 0.51 
LV EDVI (mL/m2) 57.2 ± 10.6 60.2 ± 10.6 53.9 ± 9.7 0.001 
LV ESVI (mL/m2) 23.2 ± 5.1 25.0 ± 4.8 21.2 ± 4.6 < 0.001 
LV EF (%) 59.5 ± 4.7 58.4 ± 4.5 60.8 ± 4.5 0.003 
Global longitudinal strain (%) -15.4 ± 3.2 -14.5 ± 2.9 -16.4 ± 3.3 0.001 
Global circumferential strain (%) -16.2 ± 3.4 -15.8 ± 3.2 -16.5 ± 3.5 0.23 
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Global radial strain (%) 42.1 ± 10.5 40.0 ± 9.5 44.4 ± 11.2 0.016 
Global area strain (%) -28.0 ± 5.0 -27.0 ± 4.7 -29.1 ± 5.1 0.017 
3D: 3-dimensional; BP: blood pressure; CT: computed tomography; EDVI: end-diastolic volume 
index; ESVI: end-systolic volume index; EF: ejection fraction; LV: left ventricular 
 
3.3.1 Determinants of epicardial adipose tissue volume 
 To identify independent determinants of EAT volume, all significant univariable 
determinants (BMI, waist/hip ratio and systolic blood pressure) were simultaneously entered 
into a multiple linear regression model. Table 2 shows that only measures of obesity (BMI 
[standardized β = 0.230, p = 0.007] and waist/hip ratio [standardized β = 0.266, p = 0.001]) 
were independently associated with larger EAT volume. 
 
Table 2. Univariable and multivariable linear regression models for epicardial 
adipose tissue volume 
 Univariable Multivariable 
Variable Standardized β p value Standardized β p value 
BMI 0.382 < 0.001 0.230 0.007 
Waist/hip ratio 0.359 < 0.001 0.266 0.001 
Systolic BP 0.305 < 0.001 0.129 0.18 
Diastolic BP 0.316 < 0.001 0.131 0.17 
BMI: body mass index; BP: blood pressure 
3.3.2 Determinants of three-dimensional multidirectional global strain 
 Table 3 summarizes all the univariable and multivariable determinants of 3D GLS. 
On univariable analysis, patients with coronary atherosclerosis had significantly lower 3D 
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GLS (-14.9 ± 3.1 vs. -16.1 ± 3.2%, p = 0.041). However, there was a non-significant 
association between 3D GLS and Agatston calcium score (r = 0.125, p = 0.16). Figure 3 
shows the correlation between EAT volume and 3D GLS. 
 
Table 3. Univariable and multivariable linear regression models for 3-dimensional 
global longitudinal strain 
 Univariable Multivariable 
 Standardized β p value Standardized β p value 
Male gender 0.294 0.001 0.114 0.23 
Hypertension 0.180 0.040 0.115 0.14 
Diabetes 0.164 0.06 0.080 0.26 
BMI 0.215 0.014 -0.108 0.17 
Waist/hip ratio 0.361 < 0.001 0.080 0.38 
Systolic BP 0.324 < 0.001 0.064 0.46 
Diastolic BP 0.298 0.001 0.078 0.34 
LV ESVI 0.350 < 0.001 0.213 0.008 
Presence of coronary 
atherosclerosis 
0.179 0.041 -0.016 0.83 
Epicardial adipose 
tissue volume 
0.601 < 0.001 0.512 < 0.001 
BMI: body mass index; BP: blood pressure; ESVI: end-systolic volume index; LV: left 
ventricular.  
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Figure 3. Correlation between epicardial adipose tissue volume and 3D global longitudinal 
strain. Patients with larger epicardial adipose tissue volume have significantly more impaired 
myocardial function despite a preserved LV EF. 3D: 3-dimensional. 
 
 
Potential confounders of 3D GLS such as presence of diabetes, hypertension and non-
obstructive CAD were included into the multivariable analysis. Only EAT volume 
(standardized β = 0.512, p < 0.001) and LV ESVI (standardized β = 0.213, p = 0.008) were 
independent determinants of 3D GLS (Table 3). Based on the standardized β, EAT volume 
was the strongest predictor of 3D GLS. Similarly, EAT volume was an independent 
determinant of 3D GCS (Table 4), GRS (Table 5) and GAS (Table 6). 
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Table 4. Univariable and multivariable linear regression models for 3-dimensional 
global circumferential strain 
 Univariable Multivariable 
 Standardized β p value Standardized β p value 
Hypertension 0.299 0.001 0.243 0.003 
Diabetes 0.228 0.009 0.090 0.25 
BMI 0.283 0.001 -0.011 0.90 
Waist/hip ratio 0.271 0.002 0.102 0.21 
Systolic BP 0.230 0.009 -0.072 0.43 
Diastolic BP 0.233 0.008 0.107 0.23 
LV mass index -0.194 0.027 -0.179 0.024 
LV ESVI 0.429 < 0.001 0.350 < 0.001 
Presence of coronary 
atherosclerosis 
0.055 0.54 -0.061 0.42 
EAT volume 0.375 < 0.001 0.242 0.006 
BMI: body mass index; BP: blood pressure; EAT: epicardial adipose tissue; ESVI: end-
systolic volume index; LV: left ventricular.  
 
Table 5. Univariable and multivariable linear regression models for 3-dimensional 
global radial strain 
 Univariable Multivariable 
 Standardized β p value Standardized β p value 
Male gender -0.211 0.016 0.020 0.83 
Hypertension -0.245 0.005 -0.179 0.022 
Diabetes -0.220 0.012 -0.088 0.22 
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BMI -0.296 0.001 0.070 0.39 
Waist/hip ratio -0.353 < 0.001 -0.149 0.10 
Systolic BP -0.283 0.001 0.041 0.63 
Diastolic BP -0.297 0.001 -0.126 0.12 
LV mass index 0.186 0.034 0.166 0.024 
LVESVI -0.393 < 0.001 -0.312 < 0.001 
Presence of coronary 
atherosclerosis 
-0.115 0.19 0.051 0.47 
EAT volume -0.546 < 0.001 -0.422 < 0.001 
BMI: body mass index; BP: blood pressure; EAT: epicardial adipose tissue; ESVI: end-
systolic volume index; LV: left ventricular.  
 
Table 6. Univariable and multivariable linear regression models for 3-dimensional 
global area strain 
 Univariable Multivariable 
 Standardized β p value Standardized β p value 
Male gender 0.209 0.017 0.006 0.95 
Hypertension 0.252 0.004 0.179 0.022 
Diabetes 0.221 0.011 0.087 0.23 
BMI 0.308 < 0.001 -0.053 0.52 
Waist/hip ratio 0.341 < 0.001 0.116 0.20 
Systolic BP 0.289 0.001 -0.032 0.71 
Diastolic BP 0.302 < 0.001 0.123 0.13 
LV mass index -0.206 0.019 -0.174 0.018 
LV ESVI 0.374 < 0.001 0.284 < 0.001 
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Presence of coronary 
atherosclerosis 
0.133 0.13 -0.027 0.70 
EAT volume 0.558 < 0.001 0.428 < 0.001 
BMI: body mass index; BP: blood pressure; EAT: epicardial adipose tissue; ESVI: end-
systolic volume index; LV: left ventricular.  
 
3.3.3 Subgroup analyses 
A subgroup analysis was performed in 39 patients without diabetes, hypertension and 
any coronary atherosclerosis on cardiac CT as these co-morbidities could affect strain. 
Similarly, EAT volume was significantly correlated with 3D GLS (r = 0.538, p < 0.001), 
GCS (r = 0.421, p = 0.008), GRS (r = -0.579, p < 0.001), and GAS (r = 0.582, p < 0.001). On 
multivariable analyses, EAT volume was an independent determinant of 3D GLS 
(standardized β = 0.398, p = 0.008). Although not significant, larger EAT volume trended 
towards lower 3D GCS (standardized β = 0.126, p = 0.51), GRS (standardized β = -0.341, p = 
0.076), and GAS (standardized β = 0.345, p = 0.070). 
Another subgroup analysis was performed in 40 patients with BMI ≤ 25.0 kg/m2 as 
obesity can affect image quality and the accuracy of strain measurements. Similarly, EAT 
volume was significantly correlated with 3D GLS (r = 0.668, p < 0.001), GCS (r = 0.499, p = 
0.001), GRS (r = -0.618, p < 0.001), and GAS (r = 0.629, p < 0.001). On multivariable 
analyses, EAT volume was an independent determinant of 3D GLS (standardized β = 0.414, 
p = 0.006), GRS (standardized β = -0.547, p = 0.006), and GAS (standardized β = 0.575, p = 
0.003). There was also a trend for larger EAT volume and more impaired 3D GCS 
(standardized β = 0.215, p = 0.21). 
Finally, increased EAT volume may have a direct mechanistic effect on 3D 
multidirectional global strain by “constricting” LV systolic and diastolic volumes. However, 
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there were no correlations between EAT volume and LV EDVI (r = -0.09, p = 0.29) or LV 
ESVI (r = 0.08, p = 0.35). Furthermore, unlike pericardial constriction, early diastolic 
velocities (E1) by tissue Doppler imaging are usually preserved or even supranormal, there 
were inverse relationships between EAT volume and septal E1 (r = -0.263, p = 0.002) and 
lateral E1 velocities (r = -0.285, p = 0.001). Therefore, increased EAT volume was unlikely to 
impair 3D multidirectional global strain by physically “constricting” LV systole and diastole. 
 
3.3.4 Measurement variabilities 
 Table 7 outlines the intra- and interobserver measurement variabilities for EAT 
volume and 3D multidirectional global strain analyses. 
 
Table 7. Intraobserver and interobserver measurement variabilities for epicardial 
adipose tissue volume and 3-dimensional multidirectional global strain 
Variable Intraobserver     
Absolute Difference 
Interobserver     
Absolute Difference 
EAT volume (cm3) 0.9 ± 1.0 1.7 ± 1.7 
3D global longitudinal strain (%) 1.3 ± 1.3 2.0 ± 1.6 
3D global circumferential strain (%) 3.4 ± 2.3 3.7 ± 2.3 
3D global radial strain (%) 8.3 ± 5.9 9.2 ± 6.6 
3D global area strain (%) 3.8 ± 2.8 4.3 ± 3.3 
EAT: epicardial adipose tissue; 3D: 3-dimensional 
 
3.4 Discussion 
The present study sought to determine the association between EAT volume and 
myocardial function using 3D multidirectional global strain. To our knowledge, the present 
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study was the first to demonstrate that increased EAT volume was independently associated 
with lower 3D multidirectional global strain in patients with low risk chest pain and 
preserved LV EF. Even though other measures of obesity (defined as increased BMI or 
waist/hip ratio) were independently associated with larger EAT volume, only EAT volume 
was associated with impaired LV strain. In addition, the association between EAT volume 
and LV strain was independent of other confounders of strain such as coronary 
atherosclerosis, hypertension, diabetes or image quality. Finally, the observed association 
between EAT and myocardial contractile function was likely secondary to EAT and its role in 
myocardial lipid and energy homeostasis, steatosis and lipotoxicity, rather than a direct 
mechanistic effect in physically “constricting” LV systole and diastole. 
 
3.4.1 Epicardial adipose tissues and coronary artery disease 
Consistent with current literature (61, 178), this present study demonstrated that 
patients with coronary atherosclerosis had significantly larger EAT volume. However, the 
present study is the first to demonstrate an inverse relationship between EAT volume and 
myocardial contractile function. 
One of the major strength of the present study was the exclusion of significant CAD 
as a potential confounding factor that could have impaired myocardial contractility. This was 
confirmed with the subgroup analysis where EAT was still associated with impaired LV 
strain in patients without any coronary atherosclerosis on the contrast-enhanced cardiac CT. 
This highlights the pathophysiological role of EAT on myocardium independent of its effect 
on coronary atherosclerosis. 
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3.4.2 Epicardial adipose tissue, myocardial steatosis and contractile dysfunction 
Diabetes and obesity can lead to extra cardiac and intramyocardial TG accumulation 
(i.e. steatosis) under conditions of excess free fatty acids (87, 95). These excess fatty acids 
could directly diffuse from EAT to myocardium and these are shunted into non-oxidative 
pathways and lead to accumulation of toxic intermediates such as diacylglycerol and 
ceramide that disrupt cellular signaling and cause apoptosis, fibrosis and myocardial 
contractile dysfunction (7, 15, 87, 94, 95). 
 Although previous studies have shown that increased EAT was associated with 
increased LV mass and diastolic dysfunction (80, 84, 182), this present study demonstrated 
an inverse independent relationship between EAT and myocardial contractility. Even when 
patients with diabetes, hypertension and coronary atherosclerosis were excluded, EAT 
volume was still an independent determinant of longitudinal myocardial function.  
 
3.4.3 Other potential confounding factors of strain measurement 
 3D STE is a relatively new imaging modality and it is not directly comparable to 2D 
STE (148). The feasibility in successfully analyzing 3D myocardial strain is lower (148), and 
obesity can reduce signal-to-noise ratio and may artificially reduce the absolute strain 
measurements (183). To reduce the false likelihood that the observed results were secondary 
to lower signal-to-noise ratio, we repeated all analyses in patients with BMI ≤ 25.0 kg/m2. 
The continuing observation of the independent association between EAT volume and 3D 
multidirectional global strain in patients with normal BMI suggested that poor image quality 
in obese patients was unlikely to be significant confounding factor. 
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3.4.4 Study limitations 
 Although we demonstrated an independent association between EAT volume and 
impaired 3D multidirectional global strain, it does not imply causality between increased 
EAT volume and reduced myocardial strain. However, previous in-vitro study has 
demonstrated that EAT explanted from guinea pigs secrete factors that inhibited isolated 
cardiomyocyte contractile function and induced insulin resistance (184). Secondly, no 
comparisons were made between the sensitivity of 2D versus 3D STE in detecting 
myocardial dysfunction. 
  
3.5 Conclusions 
 Obesity is known to be associated with myocardial dysfunction and heart failure (185-
187). Although the pathophysiology is unclear, visceral adiposity has been proposed to 
impair myocardial contractility through myocardial steatosis and lipotoxicity as seen in 
diabetic patients (182, 188). We demonstrated that EAT is associated with subclinical 
myocardial systolic dysfunction, independent of significant CAD, diabetes and hypertension, 
and is superior to other measures of obesity such as BMI and waist/hip ratio. Future studies 
should consider quantification of EAT volume when evaluating LV myocardial function and 
explore EAT as a potential target for management of patients with metabolic and diabetic 
heart disease. 
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CHAPTER FOUR 
Comparison of two-dimensional and three-dimensional speckle tracking 
echocardiography in patients without obstructive coronary artery disease, diabetes or 
hypertension 
 
4.1 Aims 
 We aimed to investigate (1) the effect of non-obstructive coronary atherosclerosis on 
subclinical myocardial systolic dysfunction in patients without diabetes or hypertension using 
2D and 3D STE, and (2) compare the sensitivity and clinical usefulness 2D versus 3D STE in 
detection of non-obstructive CAD. 
 
4.2 Methods 
4.2.1 Patient population and study protocol 
A total of 96 patients with low risk chest pain who underwent contrast-enhanced 
cardiac CT imaging and 2D and 3D echocardiographic imaging were included. Non-
obstructive CAD on cardiac CT imaging was defined as < 50% coronary stenosis, while no 
CAD was defined as zero calcium score and absence of any coronary plaques. Exclusion 
criteria included hypertension, diabetes, LV EF < 50%, previous cardiomyopathies or heart 
failure, moderate or severe valvular heart disease, congenital heart disease, history of 
previous myocardial infarction, percutaneous coronary intervention, or coronary artery 
bypass grafting, obstructive CAD on cardiac CT imaging defined as > 50% coronary stenosis, 
atrial fibrillation, and contraindications for cardiac CT examination. Contraindications for 
cardiac CT examination included supraventricular or ventricular arrhythmias, renal 
insufficiency (glomerular filtration rate <30 mL/min/1.73 m2), iodine contrast allergy, severe 
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claustrophobia, and pregnancy. Modification of Diet in Renal disease (MDMR) equation was 
used to calculate glomerular filtration rate (eGFR) (189). 
 
4.2.2 CT data acquisition 
This has been previously described (refer to section 3.2.2). 
 
4.2.3 Echocardiography 
This has been previously described (refer to section 3.2.4). The LV mass index, LV 
EDVI, and LV ESVI were calculated using the 3D dataset and corrected for body surface 
area.  
 
4.2.3.1 Three-dimensional speckle tracking echocardiography 
This has been previously described (refer to section 3.2.4.1).  
 
4.2.3.2 Two-dimensional speckle tracking echocardiography 
Peak systolic LS measurements calculated from the 2D data recorded in apical 4-
chamber, 2-chamber and long-axis views using commercial available software (EchoPAC 
version 113, GE-Vingmed, Horten, Norway). After the definition of the LV endocardial 
border was automatically defined, the endocardium was automatically tracked throughout the 
cardiac cycle. The software algorithm automatically divided the LV apical view into 6 
segments for speckle tracking throughout the cardiac cycle. GLS was obtained from each 
apical view and averaged (190). 
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4.2.4 Statistical analysis 
All continuous data were presented as mean ± standard deviation. The differences 
between patients with non-obstructive CAD and without CAD were compared using unpaired 
Student's t tests or chi-square tests, as appropriate. Multiple logistic regression analysis was 
used to identify independent associations for the presence or absence of CAD with 
univariable predictors (p < 0.10) entered in a stepwise manner into a multivariate logistic 
regression model. Comparison of receiver-operating characteristic curve analysis was used to 
determine the discriminatory value of 2D versus 3D GLS in identifying the presence of 
coronary atherosclerosis. To further compare the clinical usefulness of 2D versus 3D GLS in 
identifying the presence of coronary atherosclerosis, decision curve analysis was performed. 
For all analyses, p values < 0.05 were considered as statistical significant. All statistical 
analyses were performed using IBM SPSS Statistics, version 21.0 (Armonk, NY), STATA, 
release 15 (College Station, Texas) and R for stats, version 3.3.2 (Vienna, Austria).  
The study was approved by the ethics committee of the participating institution. 
 
4.3 Result 
The baseline clinical and echocardiographic characteristics for all the patients are 
shown in Table 8 and 9. The mean age was 51 ± 8.6 years, 56% male. 50% patients had non-
obstructive CAD. Patients with non-obstructive CAD were older (53 ± 8 vs. 49 ± 9 years, p = 
0.02) with higher resting diastolic blood pressure (81 ± 9 vs. 77 ± 9 mmHg, p = 0.03). The 
CAD patients had a mean Agatston score of 62 ± 112, 56% with 1-vessel disease, 21% with 
2-vessels and 23% with 3-vessels disease. There were no differences in other cardiac risk 
factors including gender, BMI, waist-hip ratio, hypercholesterolaemia, smoking status and 
family history of CAD between patients with or without coronary atherosclerosis.  
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Table 8 Demographics and baseline clinical characteristics. 
Variables Total 
cohort  
(n = 96) 
Patients with 
CAD 
(n = 48) 
Patients 
without CAD 
(n = 48) 
p Value 
Age, years 51 ±	9 53 ±	8 49 ±	9 0.023 
Male, % 56 65 48 0.10 
BMI, kg/m2 28 ±	6 28 ±	6 27 ±	6 0.71 
Waist-hip ratio 0.9 ±	0.07 0.9 ±	0.07 0.9 ±	0.07 0.09 
Hypercholesterolaemia, % 34 38 31 0.52 
Current Smoker, % 31 33 29 0.66 
Family history of CAD, % 31 27 35 0.38 
Systolic BP, mmHg 129 ±	15 129 ±	15 128 ±	16 0.70 
Diastolic BP, mmHg 79 ±	9 81 ±	9 77 ±	9 0.028 
Mean arterial BP, mmHg 96 ±	10 97 ±	10 94 ±	19 0.12 
Fasting blood glucose, mmol/L 5.6 ±	0.9 5.7 ±	0.8 5.7 ±	0.9 0.91 
HBA1c, % 5.6 ±	0.4 5.6 ±	0.8 5.5 ±	0.3 0.52 
Total cholesterol, mmol/L 5.1 ±	1.2 5.3 ±	1.3 4.9 ±	0.9 0.13 
LDL cholesterol, mmol/L 3.1 ±	1.1 3.2 ±	1.4 3.0 ±	0.8 0.40 
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HDL cholesterol, mmol/L 1.3 ±	0.3 1.3 ±	0.4 1.2 ±	0.3 0.38 
Triglyceride, mmol/L 1.5 ±	0.9 1.6 ±	1.0 1.5 ±	0.9 0.55 
Creatinine, µmol/L 73 ±	16 76 ±	16 70 ±	15 0.08 
eGFR, mL/min/1.73 m2 51 ±	10 50 ±	8 53 ±	11 0.09 
BMI: body mass index, BP: blood pressure, CAD: coronary artery disease, HBA1c: glycated 
haemoglobin, eGFR: glomerular filtration rate, HDL: high density lipoprotein, LDL: low 
density lipoprotein.  
 
The mean 2D GLS was -19.3 ± 2.2% and the mean 3D GLS was -15.6 ± 2.8%. 
Compared to those without CAD, the 2D and 3D GLS were lower in those with coronary 
atherosclerosis (-18.5 ± 2.2% vs. -20.1 ± 1.9%, p < 0.001; -14.9 ± 2.4% vs. -16.3 ± 3.1%, p = 
0.01). There was no difference in average E/e1 ratio and other multidirectional 3D strain 
measurements (GCS, GRS and GAS) between the two groups. 
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Table 9 Baseline two-dimensional and three-dimensional echocardiographic 
characteristics.  
Echocardiographic Variables Total 
cohort 
 
(n = 96) 
Patients 
with CAD   
 
(n = 48) 
Patients 
without 
CAD 
(n = 48) 
p Value 
3D-LV EDVI, ml/m2 57 ±	10 56 ±	10 58 ±	10 0.30 
3D-LV ESVI, ml/m2 23 ±	5 23 ±	4 23 ±	5 0.10 
LV EF, % 59 ±	5 58 ±	5 60 ±	5 0.051 
3D-LV mass indexed, g/m2 73 ±	9 73 ±	10 72 ±	8 0.41 
Mitral E wave, m/s 0.6 ±	0.2 0.6 ±	0.2 0.7 ±	0.2 0.009 
Mitral A wave, m/s 0.6 ±	0.2 0.6 ±	0.1 0.6 ±	0.2 0.67 
Transmitral E/A ratio 1.1 ±	0.3 1.0 ±	0.3 1.2 ±	0.4 0.027 
Mitral deceleration time, msec 197 ±	41 204 ±	40 191 ±	41 0.14 
Average E/e' ratio 7.7 ±	2.3 7.7 ±1.9 7.7 ±	2.6 0.19 
2D-Global longitudinal strain, % -19.3 ±	2.2 -18.5 ±	2.2 -20.1 ±	1.9 <0.001 
3D-Global longitudinal strain, % -15.6 ±	2.8 -14.9 ±	2.4 -16.3 ±	3.1 0.011 
3D-Global circumferential strain, % -16.2 ±	3.3 -16.1 ±	3.2 -16.4 ±	3.4 0.67 
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3D-Global radial strain, % 42.4 ±	9.5 41.3 ±	8.6 43.5 ±	10.3 0.24 
3D-Global area strain, % -28.2 ±	4.6 -27.6 ±	4.1 -29.0 ±	5.1 0.18 
EF: ejection fraction, EDVI: Indexed end diastolic volume, ESVI: Indexed end diastolic 
volume, LV: left ventricular. 
 
4.3.1 Predictors of coronary atherosclerosis 
To determine the predictors of coronary atherosclerosis, we performed univariate and 
multivariate analysis of association between baseline clinical and echocardiographic variables 
and coronary atherosclerosis. In the multivariable logistic regression model using 2D GLS, 
both age and 2D GLS were associated with coronary atherosclerosis (Table 10). Similarly, in 
a separate multivariate model using 3D GLS, both age and 3D GLS were associated with 
coronary atherosclerosis (Table 11). 
 
Table 10 Univariable and multivariable logistic regression analysis of association of 
two-dimensional echocardiographic variables with non-obstructive coronary artery 
disease. 
Variables Univariable analysis Multivariable analysis 
 OR (95% CI) p Value OR (95% CI) p value 
Age (per decade increase) 1.78 (1.07-2.95) 0.026 2.16 (1.20-3.90) 0.011 
eGFR, mL/min/1.73 m2 0.98 (0.96-1.00) 0.089   
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Waist-hip ratio (per 0.1 increase) 1.63 (0.91-2.93) 0.099   
Transmitral E/A ratio 0.25 (0.07-0.89) 0.032   
2D-Global longitudinal strain,%   1.45 (1.17-1.80) 0.001 1.55 (1.20-2.01) 0.001 
BP: blood pressure, CAD: coronary artery disease, CI: confidence interval, 2D: two-
dimensional, eGFR: glomerular filtration rate, OR: odd ratio 
 
Table 11 Univariable and multivariate logistic regression analysis of association of 
three-dimensional echocardiographic variables with non-obstructive coronary artery 
disease.  
Variables Univariable analysis Multivariable analysis 
 OR (95% CI) p Value OR (95% CI) p value 
Age (per decade increase) 1.78 (1.07-2.95) 0.026 2.23 (1.25-4.01) 0.007 
eGFR, mL/min/1.73 m2 0.98 (0.96-1.00) 0.089   
Waist-hip ratio (per 0.1 increase) 1.63 (0.91-2.93) 0.099   
Transmitral E/A ratio 0.25 (0.07-0.89) 0.032   
3D-Global longitudinal strain, % 1.22 (1.04-1.42) 0.014 1.21 (1.02-1.43) 0.027 
BP: blood pressure, CAD: coronary artery disease, CI: confidence interval, 3D: three-
dimensional, eGFR: glomerular filtration rate; OR: odd ratio 
Based on the receiver operating characteristic curve analysis, 2D GLS has higher area 
under the curve (0.70; p = 0.001) compared to 3D GLS (0.65; p = 0.01). However, there is no 
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significant difference between the area under the curve of 2D and 3D GLS (p = 0.44) in 
predicting non-obstructive coronary atherosclerosis. 
 
4.3.2 Decision Curve Analysis  
To evaluate and compare the clinical usefulness of 2D GLS versus 3D GLS in 
identifying coronary atherosclerosis, we performed a decision curve analysis (Figure 4). The 
key aspect of the decision curve analysis is to investigate which diagnostic strategy leads the 
highest net benefit. The grey line corresponded to the net benefit for “treat all” strategy, i.e. 
performed 2D and/or 3D GLS in all patients who presented with chest pain. Conversely, the 
solid black line corresponded to the net benefit for “treat none” strategy, i.e. do not perform 
2D and/or 3D GLS in any patients. The green dotted line reflected the model that included 
2D GLS and it showed the greatest net benefit (i.e. overall “highest” line) across most 
threshold probabilities compared to 3D GLS. In other words, 2D GLS is the best predictor of 
presence of coronary atherosclerosis as compared to 3D GLS or age in this decision curve 
analysis. 
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Figure 4 Decision curve analysis using predictive models of two-dimensional global 
longitudinal strain, three-dimensional global longitudinal strain or age 
2D: 2-dimensional; 3D: 3-dimensional; GLS: global longitudinal strain. 
 
4.4 Discussion 
The present study sought to determine whether the presence of non-obstructive CAD 
has an impact on LV myocardial strain in patients with preserved LV EF as well as assess the 
predictive values of 2D versus 3D GLS in identifying subclinical CAD in the absence of 
traditional cardiac risk factors. The strength of our study is the exclusion of known 
confounders for impaired GLS such as hypertension, diabetes and obstructive CAD. We 
demonstrated that: 1) non-obstructive coronary atherosclerosis was associated with lower 2D 
and 3D GLS; and 2) 2D GLS was superior to 3D GLS in predicting the presence of coronary 
atherosclerosis in patients with low risk chest pain. 
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4.4.1 Causes of subclinical left ventricular dysfunction  
The underlying pathophysiological process causing subclinical myocardial 
dysfunction in cardiac patients can be quite varied. Foremost, obstructive CAD resulting in 
myocardial ischaemia is well known for causing subclinical LV dysfunction despite 
preservation of conventional indices of systolic LV function and no overt infarction (154). As 
the severity of coronary stenosis increases and coronary flow becomes critically reduced in 
the subendocardium, the frequency of demand-induced ischaemia increases (154). 
Additionally, chronic repetitive ischaemia may cause chronic myocardial stunning and 
hibernation (190). However, in the setting of non-flow limiting coronary stenosis, this 
hypothesis is unlikely. Secondly, cardiac risk factors including hypertension and diabetes 
have been shown to be associated with subclinical myocardial dysfunction (151-154). These 
conditions are often associated with endothelial dysfunction leading to small vessel 
ischaemia, increased interstitial fibrosis and subsequent myocardial dysfunction. 
Compared to previous studies, our study incrementally added to the scientific 
literature by demonstrating an association between subclinical LV dysfunction assessed by 
2D and 3D GLS and non-obstructive CAD, independent of hypertension or diabetes. Though 
this association does not equate to causality, this finding suggests an alternative 
pathophysiological process that contribute to myocardial dysfunction independent of reduced 
coronary flow and other conventional cardiac risk factors such as hypertension or diabetes. 
We have previously demonstrated that patients with increased EAT volume is associated with 
subclinical LV dysfunction (191). 
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4.4.2 Two-dimensional versus three-dimensional speckle tracking echocardiography in 
assessing left ventricular function and detecting coronary atherosclerosis 
2D STE is currently the most common method in quantifying LV myocardial 
deformation. However, LV myocardial through-plane and twisting motions are known to 
potentially affect the calculation of 2D strain values (126). 3D echocardiography and STE 
may overcome these limitations and allows the calculation of LV EF, volumentric analysis, 
and simultaneous measurement of multidirectional strains in a single volume dataset (146). 
Despite being technically more demanding to acquire 3D dataset, previous studies suggested 
that quantification of 3D GLS was less time intensive compared to 2D GLS (136, 137, 145).  
However, 2D and 3D GLS are not interchangeable (137, 146-149). Previous studies 
have suggested that 3D GLS had a better correlation with LV EF compared to 2D GLS (144, 
148, 173). Furthermore, 3D STE was shown to be more accurate and reproducible than 2D 
STE, especially for radial and circumferential evaluations (145).                                                       
2D GLS has been shown to predict the presence of significant CAD (158-167, 169, 
192). Additionally, 2D GLS is inversely related to the number of stenotic coronary vessels 
(162, 163). On the other hand, the role of 3D STE in CAD is less well established with 
conflicting published results.  Li and coworkers demonstrated the 3D multidirectional strain 
was predictive of moderate and severe CAD (AUC of 0.899 and 0.896 respectively) (174). 
Sun and co-workers found opposing results where 3D multi-directional peak strains were not 
diagnostic of CAD (defined as > 25% coronary stenosis) in patients with suspected angina 
(175). However, they found that a composite measurement of peak LS and time to peak LS 
was predictive of mild-severe CAD (AUC of 0.692) (175). To our best knowledge, this is the 
first study to compare 2D versus 3D STE for the detection of non-obstructive coronary 
atherosclerosis in patients with low risk chest pain. We sought to compare the sensitivity and 
clinical usefulness of 2D versus 3D GLS to detect the subtlest of differences in patients with 
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no CAD versus non-obstructive CAD, and without any potential confounders such as 
hypertension or diabetes. We demonstrated that both 2D and 3D GLS were lower in patients 
with non-obstructive CAD (receiver operating characteristic curve with area under the curve 
of 0.70, 0.65 respectively), but 3D GLS failed to demonstrate superiority over 2D GLS on 
decision curve analysis. Our findings are in contrary to previous  studies which demonstrated 
the superiority of 3D over 2D STE in terms of LV function assessment (144, 145, 148, 173). 
This could partly be explained by the inherent technical difficulty of 3D STE as its temporal 
and spatial resolutions are lower compared to 2D STE (140).  Even though lower frame rate 
in 3D STE has not been shown to affect accuracy of strain measurement by Yodwut and co-
workers (142), the generalizability of their results may be limited due to small patient sample 
size of only 16 normal volunteers and 11 patients.  In contrast, our experience suggested 
higher technical challenges in the acquisition and analysis of 3D speckle tracking in a much 
larger real-life clinical patient cohort.  In addition, stitch artefacts may be unavoidable in 
uncooperative patients and in those with cardiac arrhythmias i.e. atrial fibrillation (140). 
However, in our study, all 3D images were obtained with breath holding to avoid stitch 
artefacts, and patients with cardiac arrhythmias were exclusion by the study design. 
Therefore, we would expect much lower 3D STE feasibility in routine clinical practice. 
 
4.5 Conclusions 
Non-obstructive CAD is an independent determinant of subclinical LV dysfunction. 
Despite the potential theoretical advantages of 3D STE, 2D STE is superior in predicting 
coronary atherosclerosis in patients with low risk chest pain without the presence of 
confounding co-morbidities such as hypertension and diabetes. Further larger studies are 
needed to assess the clinical applicability of early diagnosis and management of non-
obstructive CAD. 
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CHAPTER FIVE   
Conclusions of research project 
GLS has been shown to be a useful echocardiographic parameter to refine risk 
stratification of patients with low risk chest pain. In our study, 2D STE seems to be superior 
to 3D STE in predicting coronary atherosclerosis in patients with no significant conventional 
cardiac risk factors such as hypertension and diabetes. Speckle tracking echocardiographic 
technique is relatively easy to use and is readily available in most echocardiography 
laboratories, and could be incorporated into daily routine clinical practice. 
 Both non-obstructive CAD and EAT are independent determinants of GLS in our 
studies. This added to the body of evidence in the current literature on EAT and coronary 
atherosclerosis and myocardial dysfunction. Though the association between EAT and 
coronary atherosclerosis has been widely reported, our studies suggested a separate 
pathological process independent of coronary ischaemia that leads to subclinical myocardial 
dysfunction. It has been proposed to be secondary to abnormal myocardial lipid and energy 
homeostasis, steatosis and lipotoxicity. EAT and non-flowing limiting coronary 
atherosclerosis may share these common pathophysiological pathways towards subclinical 
LV dysfunction.  
In conclusion, we highlight the potential role of EAT and non-obstructive coronary 
atherosclerosis in the pathogenesis of subclinical myocardial dysfunction. Future studies are 
needed to further validate these determinants of myocardial deformation and the clinical 
applicability and benefit of identifying and managing these non-conventional cardiac “risk 
factors” for patients with low risk chest pain. 
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